BOS-580
BOS-580 is a long-acting fibroblast growth factor 21 analog that can be injected once monthly.[1][2][3] It was acquired by Boston Pharmaceuticals from Novartis in 2020.[4]
References[edit]
- ^ Raptis, Dimitrios D.; Mantzoros, Christos S.; Polyzos, Stergios A. (22 January 2023). "Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease". Therapeutics and Clinical Risk Management. 19: 77–96. doi:10.2147/TCRM.S352008. PMC 9879042. PMID 36713291.
- ^ Yang, Ranyao; Xu, Aimin; Kharitonenkov, Alexei (1 January 2022). "Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver". The Journal of Clinical Endocrinology & Metabolism. 107 (1): e417–e419. doi:10.1210/clinem/dgab686. PMC 8684496. PMID 34529079.
- ^ Jin, Leigang; Yang, Ranyao; Geng, Leiluo; Xu, Aimin (20 January 2023). "Fibroblast Growth Factor–Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications". Annual Review of Pharmacology and Toxicology. 63 (1): 359–382. doi:10.1146/annurev-pharmtox-032322-093904. PMID 36100222. S2CID 252221297.
- ^ Timmins, Peter (January 2021). "Industry Update: the latest developments in the field of therapeutic delivery, September 2020". Therapeutic Delivery. 12 (1): 7–20. doi:10.4155/tde-2020-0124. PMID 33397151. S2CID 230661884.